CLINICAL AND PHARMACODYNAMIC BIOMARKER RESULTS FROM PORTER, A MULTI-COHORT PHASE 1 PLATFORM TRIAL OF COMBINATION IMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS

被引：0

作者：

Galsky, Matthew ^{[1
]}

Autio, Karen ^{[2
]}

Wentzel, Kristopher ^{[3
]}

Graff, Julie ^{[4
]}

Friedlander, Terence ^{[5
]}

Densmore, Julie ^{[6
]}

Cabanski, Christopher ^{[6
]}

Shotts, Kristin ^{[6
]}

Howes, Tim ^{[6
]}

Yu, Jia ^{[6
]}

Eisenbeisz, Elaine ^{[6
]}

Spasic, Marko ^{[6
]}

Maddock, Stephen ^{[6
]}

DaSilva, Diane ^{[6
]}

Kumar, Dinesh ^{[6
]}

Moore, Jonni ^{[7
]}

Schretzenmair, Richard ^{[8
]}

Lata, Jennifer ^{[8
]}

Xu, Arron ^{[8
]}

Reuschel, Emma ^{[8
]}

Wani, Snehal ^{[8
]}

Morrow, Matthew ^{[8
]}

Skolnik, Jeffrey ^{[8
]}

Santulli-Marotto, Sandra ^{[6
]}

Padron, Lacey ^{[6
]}

Butterfield, Lisa ^{[6
]}

LaVallee, Theresa ^{[6
]}

Bucktrout, Samantha ^{[6
]}

Yellin, Michael ^{[9
]}

Keler, Tibor ^{[9
]}

Salvador, Lisa ^{[10
]}

O'Donnell-Tormey, Jill ^{[11
]}

Lucey, Vanessa ^{[11
]}

Fairchild, Justin ^{[6
]}

Dugan, Ute ^{[6
]}

Bhardwaj, Nina ^{[1
]}

Subudhi, Sumit ^{[12
]}

Fong, Lawrence ^{[5
]}

机构：

[1] Mt Sinai Med Ctr, New York, NY 10029 USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Angeles Clin, Los Angeles, CA USA

[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Parker Inst Canc Immunotherapy, San Francisco, CA USA

[7] Univ Penn, Philadelphia, PA 19104 USA

[8] Inovio Pharmaceut, Plymouth Meeting, PA USA

[9] Celldex Therapeut, Hampton, NJ USA

[10] Bristol Myers Squibb, Princeton, NJ USA

[11] Canc Res Inst, New York, NY USA

[12] MD Anderson, Houston, TX USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0555

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

555

引用

页码：A580 / A580

页数：1

共 50 条

[1] BIOMARKER CORRELATES OF CLINICAL RESPONSE WITH FLT3L/NIVO BACKBONE TREATMENT IN THE MULTI-COHORT PHASE 1 PORTER PLATFORM TRIAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Shotts, Kristin
Howes, Timothy
Yu, Jia
Densmore, Julie
Da Silva, Diane
Kumar, Dinesh
Santulli-Marotto, Sandra
Cabanski, Christopher
Eisenbeisz, Elaine
Ivison, Geoffrey
Mayer, Aaron
Moore, Jonni
Jones, Derek
Kraynyak, Kimberly
Dolgoter, Alex
Chen, Richard
Butterfield, Lisa
LaVallee, Theresa
Bucktrout, Samantha
Padron, Lacey
Dugan, Ute
Yellin, Michael
Keler, Tibor
O'Donnell-Tormey, Jill
Fairchild, Justin
Salvador, Lisa
Wentzel, Kristopher
Fong, Lawrence
Subudhi, Sumit
Bhardwaj, Nina
Autio, Karen
Galsky, Matthew
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A585 - A585
[2] Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
Dahut, William L.
Madan, Ravi A.
Karakunnel, Joyson J.
Adelberg, David
Gulley, James L.
Turkbey, Ismail B.
Chau, Cindy H.
Spencer, Shawn D.
Mulquin, Marcia
Wright, John
Parnes, Howard L.
Steinberg, Seth M.
Choyke, Peter L.
Figg, William D.
BJU INTERNATIONAL, 2013, 111 (08) : 1269 - 1280
[3] Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
Liaw, Bobby C.
Tsao, Che-Kai
Seng, Sonia
Jun, Tomi
Gong, Yixuan
Galsky, Matthew D.
Oh, William K.
ONCOLOGIST, 2022, : 366 - 367+e218
[4] Phase 1 efficacy and pharmacodynamic results of exicorilant plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Morris, Michael J.
Linch, Mark David
Crabb, Simon J.
Beer, Tomasz M.
Heath, Elisabeth I.
Gordon, Michael S.
De Bono, Johann S.
Pashova, Hristina I.
Tudor, Iulia Cristina
Greenstein, Andrew E.
Mann, Grace
Liu, Glenn
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[5] Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
Zurita, A. J.
George, D. J.
Shore, N. D.
Liu, G.
Wilding, G.
Hutson, T. E.
Kozloff, M.
Mathew, P.
Harmon, C. S.
Wang, S. L.
Chen, I.
Maneval, E. Chow
Logothetis, C. J.
ANNALS OF ONCOLOGY, 2012, 23 (03) : 688 - 694
[6] Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer
Lin, Jianqing
Sinibaldi, Victoria J.
Carducci, Michael A.
Denmeade, Samuel
Song, Danny
DeWeese, Theodore
Eisenberger, Mario A.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) : 670 - 675
[7] Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel
Elumalai, T.
Barker, C.
Elliott, T.
Malik, J.
Tran, A.
Hudson, A.
Song, Y. P.
Patel, K.
Lyons, J.
Hoskin, P.
Choudhury, A.
Mistry, H.
CLINICAL ONCOLOGY, 2022, 34 (07) : E291 - E297
[8] A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER)
Nissola, Leo
Autio, Karen
Bhardwaj, Nina
Galsky, Matthew
Wentzel, Kristopher
Lucey, Vanessa
Selinsky, Cheryl
Perry, Christopher
Cabanski, Christopher
Bitton, Ari
Fairchild, Justin
Horak, Christine
Skolnik, Jeffrey
Yellin, Michael
Dugan, Ute
Ibrahim, Ramy
Fong, Lawrence
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[9] A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
Armstrong, Andrew J.
Shen, Tong
Halabi, Susan
Kemeny, Gabor
Bitting, Rhonda L.
Kartcheske, Patricia
Embree, Elizabeth
Morris, Karla
Winters, Carolyn
Jaffe, Tracy
Fleming, Mark
George, Daniel J.
CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 397 - 406
[10] A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
Armstrong, Andrew J.
Shen, Tong
Halabi, Susan
Kemeny, Gabor
Bitting, Rhonda Lynn
Kartcheske, Patricia
Embree, Elizabeth
Morris, Karla
Winters, Carolyn
Jaffe, Tracy
Fleming, Mark T.
George, Daniel J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)

← 1 2 3 4 5 →